Seeing that many netizens are still asking questions about IMS drug database, I don't know that IMS health no longer exists, and it is meaningless to ask the source of IMS drug data! In order to popularize knowledge points, IMS drug database, which means IMS Health, merged with Quintiles on 20 16 to become QuintilesIMS, and changed its name to IQVIA on 20 17.
Next, I will talk about IQVIA (formerly IMS) drug database.
You may not know what this database is like. Today, the author makes a multi-dimensional analysis on the product composition, data source, data retrieval results, value-added services and social evaluation of IQVIA (formerly IMS) drug database to help everyone have a new understanding of it.
In order to make people understand the drug database of IQVIA (formerly IMS) more intuitively, the author introduces a drug database (Rong Yun Medicine Database) with the widest coverage of domestic customers as a comparison.
1. Product composition
IQVIA (formerly IMS) drug database: it consists of three sections: business consultation, drug research and development, and comprehensive services.
Rong Yun Pharmaceutical Database (pharnexcloud): It consists of 10 sections, including drug research and development, drugs on the market, drug sales, market information, consistency evaluation, raw materials, medical devices, production inspection, rational drug use, medical literature, etc.
2. Data source
Both of them involve thousands of data sources, including but not limited to (① medical information: laboratory research, internal meetings, professional reports, patents, trademarks, technical implementation documents, academic meetings, technical reports, scientific journals, documents, etc. ② Medical database: heterogeneous resources, medical big data processing based on cloud computing and cloud storage, etc. ③ Medical data: global countries or regions, information, corporate announcements, medical conferences, news information, declining investor pressure, company annual reports, medical care, pharmaceutical companies, medical magazines and other resources. )
3. Data display results
We make an intuitive comparison between the most available data of IQVIA database in China (CHPA, China Hospital Drug Statistics Report) and pharnexcloud's (National Hospital Sales Data).
IQVIA database (China Hospital Drug Statistics Report) is designed based on 9454 hospitals (≥ 100 beds), covering 255 cities. There are only about 1000 sample hospitals, and the total number that can be calculated is about 8,000.
IQVIA database contains more than 80 thousand global medical transaction information;
Pharnexcloud database (national hospital sales data), which is based on the sample design of 10000 hospitals (secondary hospitals and above), covering 24 provinces and all key urban areas in China, with more than 2200 stratified samples. More than 9,000 sample hospitals can be estimated through hierarchical amplification of professional computing models. This is the coverage scale that other databases at home and abroad can't match.
Pharne cloud database global medical transaction information 19653 (the author has insufficient authority and can only find the data of 202 1 so far), so it can be inferred that pharne cloud global medical transaction information data is also higher than IQVIA database.
Pharnexcloud: ① Specialized personnel meet the demand, give one-on-one guidance, and professional teams solve industry data problems. (2) Salon, lecture tour, summit, project transaction, demand docking and other activities support, VIP joins their ecological chain of drug integration circle (currently doing very well in China).
Pharnexcloud: At present, it is the most selected medical database for domestic pharmaceutical companies. Because of its comprehensive functions and data, it has become the hottest medical database in the market, among which the drug research and development section and drug sales data section are the top in the industry.
The author says it's useless to have more. The most important thing is to take the demand point of medical database and try to compare its data in person to verify the reliability of the data source.